6990

Sichuan Kelun-Biotech

6990.HK kelun-biotech.com + Research + Basket
Healthcare · Biotechnology
Employees 2,300
Fiscal year end December
Address No. 666 Xinhua Avenue, Chengdu, China
Charts Income waterfall Balance sheet Capital intensity Insider trading Price histogram Stock regimes
465.00
+10.20 (+2.24%)
HKD · HK
52-week range
339.60
562.50
Trading at 56% of the 52-week range
Market Cap
108.71B
P/E Ratio
631.67
Forward P/E
0.00
Book Value
26.89
Div. Yield
N/A
% Institutions
27.79%
% Insiders
58.88%

1 Year

+12.5%

3 Year

+421.6%

10 Year

+644.0%
Description

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People's Republic of China and internationally. The company's product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC targeting advanced solid tumors; SKB410/MK-3120, a novel Nectin-4 ADC targeting advanced solid tumors; and SKB571/MK-2750, a novel bsADC primarily targeting various solid tumors, such as LC and CRC. The company also develops SKB518, SKB535/MK-6204 and SKB445, which are novel ADC drugs with potential FIC targets; SKB500 and SKB501, which are novel ADC drugs with verified targets but differentiated payload-linker strategies; SKB107, an RDC targeting tumor bone metastases; Tagitanlimab, PD-L1 mAb for its immunotherapy franchise; Cetuximab N01, a recombinant EGFR human-mouse chimeric mAb; A400, a novel selective RET inhibitor; and A296, a novel small molecule STING agonist. It has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; Windward Bio AG; and Ellipses Pharma Limited. The company has a strategic partnership with Crescent Biopharma, Inc. The company was incorporated in 2016 and is headquartered in Chengdu, the People's Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.

Actions

Open action list

Add an action for 6990.HK, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Junyou Ge President, CEO, COO, GM & Executive Director 1972
Mr. Zejian Zhou CFO & Company Secretary 1982
Mr. Nan Chao Ding Deputy GM & Chief Marketing Officer 1986
Mr. Yi Feng Deputy GM, Chief Strategy Officer & Senior VP 1966
Dr. Xiangyang Tan Deputy GM & Chief Scientific Officer of Large Molecule 1963
Dr. Xiaoping Jin Deputy GM & Chief Medical Officer 1978
Dr. Wensheng Yu Deputy General Manager & Chief Science Officer of Small Molecule 1967
Mr. Wei Chen Deputy General Manager 1975

Financial Highlights

▼
Market Cap: $108.71B
EBITDA: $59.17M
P/E Ratio: $631.67
Book Value: $26.89
Earnings/Share: $0.00
Profit Margin: 7.25%
Operating Margin: 22.37%
ROA (TTM): -0.04%
ROE (TTM): 2.92%
Revenue (TTM): $2.09B
Revenue/Share (TTM): $8.94
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 2.90%

Valuation Metrics

Enterprise Value: $103.19B
Trailing P/E: 631.67
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 176.82M
Shares Float: 97.58M
% Insiders: 58.88%
% Institutions: 27.79%

Stock Price History

▼
Open price histogram Stock regimes

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$2.06B
Cost of Goods Sold
adjust
$-579.14M
Gross Profit
subtotal
$1.48B
SG&A
adjust
$-46.65M
R&D
adjust
$-1.32B
Other Operating Expense
adjust
$-578.65M
Operating Income
subtotal
$-466.19M
Other / Non-Operating Items
adjust
$84.22M
Net Income
subtotal
$-381.97M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about 6990.HK!